TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16372263

Group type: EXPERIMENTAL
Intervention: Oral vitamin C supplementation (250 mg three times per week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with normal renal function
Number of subjects: 0
Study: 14662011

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/d)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/d)
Number of subjects: 11
Study: 11113618

Group type: EXPERIMENTAL
Intervention: Novel antioxidant supplements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutritional supplements
Number of subjects: 0
Study: 9026680

Group type: EXPERIMENTAL
Intervention: Bed-time ultralente insulin (0.15-0.2 U/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: NPH insulin (0.15-0.2 U/kg)
Number of subjects: 0
Study: 7930304

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Intranasal corticosteroids
Number of subjects: 1000
Study: 3370851

Group type: EXPERIMENTAL
Intervention: L‐menthol
Number of subjects: 40

Group type: COMPARATOR
Intervention: D‐isomenthol
Number of subjects: 40

Group type: COMPARATOR
Intervention: D‐neomenthol
Number of subjects: 40
Study: 31625399

Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 675

Group type: COMPARATOR
Intervention: Colposcopy
Number of subjects: 675

Group type: COMPARATOR
Intervention: Pap-smear
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: HPV-positive women
Number of subjects: 675

Group type: COMPARATOR
Intervention: HPV-negative women
Number of subjects: 675
Study: 30152415

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care group (PCG)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Usual care group (UCG)
Number of subjects: 153
Study: 28259590

Group type: EXPERIMENTAL
Intervention: 1mg/day of Plasmalogen (Pls) purified from scallop
Number of subjects: 328

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study: 26444127

Group type: EXPERIMENTAL
Intervention: Copper IUD
Number of subjects: 703

Group type: COMPARATOR
Intervention: Levonorgestrel IUD
Number of subjects: 703
Study: 23277307

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention with drug eluting stents (DES-PCI)
Number of subjects: 1900

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1900
Study: 21623673

Group type: EXPERIMENTAL
Intervention: Somatostatin analog (SA) treatment for 4 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (healthy subjects), N=12
Number of subjects: 12
Study: 19257967

Group type: EXPERIMENTAL
Intervention: Thymus mature dendritic cells (mDC) in MG patients
Number of subjects: 39

Group type: COMPARATOR
Intervention: Thymus mature dendritic cells (mDC) in control patients
Number of subjects: 39
Study: 16492920

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 1549

Group type: EXPERIMENTAL
Intervention: XPC polymorphisms (R492H, A499V, K939Q)
Number of subjects: 1549

Group type: COMPARATOR
Intervention: None of the studied SNPs
Number of subjects: 1549
Study: 12951363

Group type: EXPERIMENTAL
Intervention: TLC diet (28% fat)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Western diet (38% fat)
Number of subjects: 18
Study: 11110851

Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (3.4 g per day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (6.8 g per day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (9 g olive oil)
Number of subjects: 60
Study: 7761220

Group type: EXPERIMENTAL
Intervention: HIDS phototherapy (26 to 30 microW/cm2 per nanometer)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional phototherapy (CPT) (7 to 10 microW/cm2 per nanometer)
Number of subjects: 50
Study: 2186660

Group type: EXPERIMENTAL
Intervention: Oral diazepam (0.5 mg/kg)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Oral trimeprazine (4 mg/kg)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Oral pentobarbitone (3 mg/kg)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 450929

Group type: EXPERIMENTAL
Intervention: Scopolamine (8 microgram/kg)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Methamphetamine (0.2 mg/kg or 0.3 mg/kg)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Physostigmine (32 microgram/kg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 31486832

Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg/m2 every 21 days) plus Sorafenib (400 mg orally twice daily)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Sorafenib alone
Number of subjects: 356
Study: 28457021

Group type: EXPERIMENTAL
Intervention: Clinical pharmacist (CP) intervention
Number of subjects: 593

Group type: COMPARATOR
Intervention: Usual care (prospective control)
Number of subjects: 593

Group type: COMPARATOR
Intervention: Usual care (retrospective control)
Number of subjects: 593
Study: 26366966

Group type: EXPERIMENTAL
Intervention: Botox (1:3)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Botox (1:1.7)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Dysport
Number of subjects: 46
Study: 23886720

Group type: EXPERIMENTAL
Intervention: Dental health education from the Dentist (Group A)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dental health education from the class teacher trained by the Dentist (Group B)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dental health education from dental residents dressed as cartoon characters (Group C)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (Group D)
Number of subjects: 100
Study: 21742105

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 2974

Group type: EXPERIMENTAL
Intervention: Bare-metal stents (BMS)
Number of subjects: 2974

Group type: COMPARATOR
Intervention: Overall lesions treated with PES and BMS
Number of subjects: 2974
Study: 19619102

Group type: EXPERIMENTAL
Intervention: PHC-based interventions for unemployed people, details on dosage and duration not available.
Number of subjects: 0
Study: 18035194

Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin 0.3%/dexamethasone 0.1% (CD) otic suspension
Number of subjects: 1072

Group type: COMPARATOR
Intervention: Polymyxin B/neomycin/hydrocortisone (PNH) otic suspension
Number of subjects: 1072
Study: 14709948

Group type: EXPERIMENTAL
Intervention: Quetiapine (200-1200 mg/d)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Risperidone (1-6 mg/d)
Number of subjects: 49
Study: 11703994

Group type: EXPERIMENTAL
Intervention: Distance walked in 6 minutes at baseline
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Distance walked in 6 minutes at 1 month
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Change in distance walked from baseline to 1 month
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Baseline distance walked
Number of subjects: 440
Study: 9645549

Group type: EXPERIMENTAL
Intervention: Lorazepam (30 microg/kg)
Number of subjects: 28
Study: 7859241

Group type: EXPERIMENTAL
Intervention: Tosufloxacin 150 mg orally three times daily
Number of subjects: 63

Group type: COMPARATOR
Intervention: Doxycycline 100 mg orally twice daily
Number of subjects: 63
Study: 2660783

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 5539179

Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 38

Group type: COMPARATOR
Intervention: Debrisoquine
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Neither drug
Number of subjects: 38
Study: 31981518

Group type: EXPERIMENTAL
Intervention: ENDOANGEL-assisted colonoscopy
Number of subjects: 704

Group type: COMPARATOR
Intervention: Unassisted colonoscopy (control)
Number of subjects: 704
Study: 31468607

Group type: EXPERIMENTAL
Intervention: Aquatic training (35 min, three times a week for 6 weeks, increasing to 45 min after 3 weeks)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Aquatic training
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 23
Study: 29119733

Group type: EXPERIMENTAL
Intervention: Fentanyl 3.5 μg/kg via slow intravenous fluid line
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Fentanyl 3.5 μg/kg via direct injection (control group)
Number of subjects: 1200
Study: 25311306

Group type: EXPERIMENTAL
Intervention: RT plus PCV chemotherapy
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Appetite loss (AP)
Number of subjects: 288
Study: 23138961

Group type: EXPERIMENTAL
Intervention: Contingency management for stimulant abstinence plus treatment as usual
Number of subjects: 176

Group type: COMPARATOR
Intervention: Treatment as usual with reinforcement for study participation only
Number of subjects: 176
Study: 21554991

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 260
Study: 19198737

Group type: EXPERIMENTAL
Intervention: Programmed physical activity
Number of subjects: 383

Group type: COMPARATOR
Intervention: Conventional school physical education (Control)
Number of subjects: 383
Study: 16968575

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg/day plus metformin 1000 mg/day (RSG + MET)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Metformin 1500 mg/day (up-titrated MET)
Number of subjects: 122
Study: 14556556

Group type: EXPERIMENTAL
Intervention: Peptamen nutriment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 10858715

Group type: EXPERIMENTAL
Intervention: 4% PRO 2000 gel
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 0.5% PRO 2000 gel
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 73
Study: 9352145

Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (rhEPO) at dosages up to 300 U/kg thrice weekly for 12 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: normal controls (28 individuals)
Number of subjects: 25
Study: 8476874

Group type: EXPERIMENTAL
Intervention: Intervention group (HIV education and counseling)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 90
Study: 4065188

Group type: EXPERIMENTAL
Intervention: Femoxetine (200 mg single dose)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Amitriptyline (50 mg single dose)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Femoxetine (600 mg/day for 10 days)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Femoxetine (600 mg/day for 10 days) with alcohol (EtOH)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 29468454

Group type: EXPERIMENTAL
Intervention: Anastrozole plus UFT (tegafur/uracil)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Anastrozole alone
Number of subjects: 57
Study: 26630391

Group type: EXPERIMENTAL
Intervention: Clozapine treatment for 8 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 28
Study: 25254301

Group type: EXPERIMENTAL
Intervention: Therapeutic rAd5 HIV‐1 gag vaccine
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Pre-ATI CA-RNA and CA-DNA
Number of subjects: 93
Study: 21500102

Group type: EXPERIMENTAL
Intervention: Increases in physical activity
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Increases in objective activity
Number of subjects: 365
Study: 19721108

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 811
Study: 17875950

Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous esmolol
Number of subjects: 50
Study: 15121485

Group type: COMPARATOR
Intervention: Aprepitant 10 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Aprepitant 30 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Aprepitant 100 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Aprepitant 300 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11673771

Group type: EXPERIMENTAL
Intervention: Test yoghurt (200 g portion containing 5 g of a novel fat emulsion + 1 g milk fat)
Number of subjects: 60
Study: 9336514

Group type: EXPERIMENTAL
Intervention: Endoscopic drainage (18 elderly and 59 younger patients)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Surgical drainage (8 elderly and 48 younger patients)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Percutaneous drainage (11 elderly and 47 younger patients)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Endoscopic nasobiliary drainage without sphincterotomy
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Elderly patients with severe cholangitis
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Elderly patients with nonsevere cholangitis
Number of subjects: 191

Group type: COMPARATOR
Intervention: Younger patients
Number of subjects: 191
Study: 7533904

Group type: EXPERIMENTAL
Intervention: Nucleoside analogs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proteinase inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental treatments
Number of subjects: 0
Study: 2438874

Group type: EXPERIMENTAL
Intervention: 20% azelaic acid (AA) applied topically twice daily for 3 months
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 387420

Group type: EXPERIMENTAL
Intervention: Brinase
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Brinase and coumarins
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Brinase (all patients considered)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Brinase (excluding 10 patients with Buerger's disease)
Number of subjects: 70
Study: 31642946

Group type: EXPERIMENTAL
Intervention: ACL intact group
Number of subjects: 16

Group type: COMPARATOR
Intervention: ACL cut group
Number of subjects: 16
Study: 31084969

Group type: EXPERIMENTAL
Intervention: Restrictive strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 27786359

Group type: EXPERIMENTAL
Intervention: Music therapy plus usual care (n=123; 76 in final analyses)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Usual care alone (n=128; 105 in final analyses)
Number of subjects: 251
Study: 25810023

Group type: EXPERIMENTAL
Intervention: 30 mg morphine administered per rectum
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 12 mg MNTX given subcutaneously before 30 mg rectal morphine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 23690938

Group type: EXPERIMENTAL
Intervention: Pharmacists' interventions
Number of subjects: 368

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 368
Study: 21875860

Group type: EXPERIMENTAL
Intervention: Biventricular (BiV) pacing
Number of subjects: 177

Group type: COMPARATOR
Intervention: Right ventricular apical (RVA) pacing
Number of subjects: 177
Study: 19176745

Group type: EXPERIMENTAL
Intervention: Low-viscosity oat bran beverage
Number of subjects: 20

Group type: COMPARATOR
Intervention: High-viscosity oat bran beverage
Number of subjects: 20
Study: 17138914

Group type: EXPERIMENTAL
Intervention: High-cost fruit and vegetable items
Number of subjects: 1355

Group type: COMPARATOR
Intervention: Low-cost fruit and vegetable items
Number of subjects: 1355

Group type: EXPERIMENTAL
Intervention: Higher income
Number of subjects: 1355

Group type: EXPERIMENTAL
Intervention: African American race
Number of subjects: 1355

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 1355
Study: 15529516

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 3700

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 3700

Group type: COMPARATOR
Intervention: Gliclazide
Number of subjects: 3700
Study: 11403367

Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg q.d.
Number of subjects: 115

Group type: COMPARATOR
Intervention: Atenolol 50 mg q.d.
Number of subjects: 115
Study: 9755349

Group type: EXPERIMENTAL
Intervention: Pain (acute pain induced by 0 degrees‐2 degrees C water immersion)
Number of subjects: 160

Group type: COMPARATOR
Intervention: No pain
Number of subjects: 160
Study: 7872033

Group type: COMPARATOR
Intervention: Neuroleptic-naive schizophrenic subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medicated subjects with tardive dyskinesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medicated subjects without tardive dyskinesia
Number of subjects: 0
Study: 3124618

Group type: EXPERIMENTAL
Intervention: Intranasal buserelin (400 micrograms 3 times a day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Subcutaneous buserelin injection (200 micrograms once daily)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Intranasal buserelin
Number of subjects: 13

Group type: COMPARATOR
Intervention: Subcutaneous buserelin
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Intranasal and subcutaneous buserelin
Number of subjects: 13
Study: 31828590

Group type: EXPERIMENTAL
Intervention: Intraarticular corticosteroid injection (IACSI)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intraarticular corticosteroid injection (IACSI) + Genicular nerve block (GNB)
Number of subjects: 40
Study: 30934041

Group type: EXPERIMENTAL
Intervention: Narrow-diameter titanium-zirconium (Ti-Zr) alloy implants
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard-diameter implants
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both groups (narrow-diameter and standard-diameter implants)
Number of subjects: 50
Study: 28166765

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Combined resistance and aerobic training
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 240
Study: 26814462

Group type: EXPERIMENTAL
Intervention: Bleaching toothpaste containing Blue Covarine (BC)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Bleaching toothpaste without Blue Covarine (WBC)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: In-office bleaching using 35% hydrogen peroxide (HP35)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: At-home bleaching with 10% carbamide peroxide (CP10)
Number of subjects: 75
Study: 23835436

Group type: EXPERIMENTAL
Intervention: PEG 3350+E
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study: 21574983

Group type: EXPERIMENTAL
Intervention: Briakinumab (200 mg at weeks 0 and 4, followed by 100 mg at week 8)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Etanercept (50 mg twice weekly at weeks 0-11)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Placebo injections matching active treatment
Number of subjects: 347
Study: 17352847

Group type: EXPERIMENTAL
Intervention: Adjunctive T3
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 17241714

Group type: EXPERIMENTAL
Intervention: JE‐PIV vaccine administered in either two or three intramuscular (IM) doses (6.0 or 12.0 mcg each)
Number of subjects: 0
Study: 15792018

Group type: EXPERIMENTAL
Intervention: Supplementation (S-group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (NS-group)
Number of subjects: 0
Study: 11692097

Group type: EXPERIMENTAL
Intervention: Active avoidance group (home visits with allergen avoidance measures)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo avoidance group (home visits with placebo measures)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (no house visits until the end of the first year)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Children with mite allergy (considered separately)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Cockroach allergen avoidance measures
Number of subjects: 104
Study: 9546944

Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7957466

Group type: EXPERIMENTAL
Intervention: Bilateral groin node dissection (BGND)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 64
Study: 2441735

Group type: EXPERIMENTAL
Intervention: Genetic amniocentesis
Number of subjects: 283

Group type: COMPARATOR
Intervention: Ultrasound scan
Number of subjects: 283
Study: 29843244

Group type: EXPERIMENTAL
Intervention: Multisensory stimulation environment (MSSE)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Individualized music sessions
Number of subjects: 21

Group type: COMPARATOR
Intervention: Both groups (MSSE and individualized music)
Number of subjects: 21
Study: 28397158

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (12-month community DPP lifestyle intervention)
Number of subjects: 223
Study: 25686143

Group type: EXPERIMENTAL
Intervention: RIN-150 (rifampicin 150 mg and isoniazid 75 mg)
Number of subjects: 28
Study: 23727264

Group type: EXPERIMENTAL
Intervention: 25 mg OCA
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 50 mg OCA
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Combined OCA groups
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 21078196

Group type: EXPERIMENTAL
Intervention: Child-focused cognitive-behavioral therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Family-focused cognitive-behavioral therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control (no therapy)
Number of subjects: 0
Study: 18822906

Group type: EXPERIMENTAL
Intervention: Bushen Er'xian Decoction (BED)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Artificial menstrual cycle therapy (Control)
Number of subjects: 60
Study: 16536187

Group type: EXPERIMENTAL
Intervention: PAC unit light cured for 1 second (Group 1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PAC unit light cured for 2 seconds (Group 2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PAC unit light cured for 3 seconds (Group 3)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PAC unit light cured for 6 seconds (Group 4)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PAC unit light cured for 12 seconds (Group 5)
Number of subjects: 20

Group type: COMPARATOR
Intervention: QTH unit light cured for 60 seconds (Group 6)
Number of subjects: 20
Study: 14519634

Group type: EXPERIMENTAL
Intervention: Adjuvant 5-fluorouracil (5-FU) therapy
Number of subjects: 309